HUNTLEY, Ill.--(BUSINESS WIRE)--Centric Medical, a new division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology, announced today that the U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance to its TARSA-LINK system, for internal bone fixation of fractures, fusions, and osteotomies in the foot and ankle. TARSA-LINK represents a unique new osteotomy wedge fusion system and joins Centric Medical’s suite of osteobiologic products.
The innovative TARSA-LINK device encompasses a polyetheretherketone (PEEK) wedge with integral bone screws, for procedures including opening wedge osteotomies of Hallux Valgus, Evans lengthening osteotomies, and metatarsal/cuneiform arthrodesis. TARSA-LINK is scheduled for limited market release in the fourth quarter of 2014, with plans for a broader product launch slated for early spring of 2015.
About Centric Medical
Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois.